Nature Communications (Jun 2019)
Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade
- Anna Morena D’Alise,
- Guido Leoni,
- Gabriella Cotugno,
- Fulvia Troise,
- Francesca Langone,
- Imma Fichera,
- Maria De Lucia,
- Lidia Avalle,
- Rosa Vitale,
- Adriano Leuzzi,
- Veronica Bignone,
- Elena Di Matteo,
- Fabio Giovanni Tucci,
- Valeria Poli,
- Armin Lahm,
- Maria Teresa Catanese,
- Antonella Folgori,
- Stefano Colloca,
- Alfredo Nicosia,
- Elisa Scarselli
Affiliations
- Anna Morena D’Alise
- Nouscom Srl
- Guido Leoni
- Nouscom Srl
- Gabriella Cotugno
- Nouscom Srl
- Fulvia Troise
- Nouscom Srl
- Francesca Langone
- Nouscom Srl
- Imma Fichera
- Nouscom Srl
- Maria De Lucia
- Nouscom Srl
- Lidia Avalle
- Department of Molecular Biotechnology and Health Sciences, University of Turin
- Rosa Vitale
- Nouscom Srl
- Adriano Leuzzi
- Nouscom Srl
- Veronica Bignone
- Nouscom Srl
- Elena Di Matteo
- Nouscom Srl
- Fabio Giovanni Tucci
- Nouscom Srl
- Valeria Poli
- Department of Molecular Biotechnology and Health Sciences, University of Turin
- Armin Lahm
- Nouscom Srl
- Maria Teresa Catanese
- Nouscom Srl
- Antonella Folgori
- Nouscom Srl
- Stefano Colloca
- Nouscom Srl
- Alfredo Nicosia
- Nouscom AG, Bäumleingasse, 18 CH-4051
- Elisa Scarselli
- Nouscom Srl
- DOI
- https://doi.org/10.1038/s41467-019-10594-2
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 12
Abstract
Vaccination against neo-antigens has resulted in an effective antitumor response in several models. Here, the authors show that delivery of larger sets of neo-antigens using an adenovirus-based vaccination platform, results in much better tumor protection when combined with checkpoint blockade in a mouse model of advanced disease.
